Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246902 | 1.00 | IDH1 (0.52) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL29603557 | 0.93 | IDH1 (0.51) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL2246209 | 0.93 | IDH1 (0.51) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL2247778 | 0.93 | IDH1 (0.51) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL2246471 | 0.91 | DYRK1A (0.47) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL8358730 | 0.91 | DYRK1A (0.47) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL29603010 | 0.91 | DYRK1A (0.47) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL2245751 | 0.89 | DYRK1A (0.46) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL29603177 | 0.89 | DYRK1A (0.46) | IDH1DYRK1ACSNK1DHDAC6HDAC3 | |
| SCHEMBL2248020 | 0.89 | DYRK1A (0.47) | IDH1DYRK1ACSNK1DHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | VTV THERAPEUTICS LLC | 2021-11-04 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10888569-B1 | Methods and compositions for treating cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-01-12 | — | — | US | disclosed |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | disclosed |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2018-10-11 | — | — | US | disclosed |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2536285-B1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2536285-B1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | disclosed |
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | IDH1 72/4885DYRK1A 3837/4885CSNK1D 1536/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | IDH1 72/4885DYRK1A 3837/4885CSNK1D 1536/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | IDH1 72/4885DYRK1A 3837/4885CSNK1D 1536/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | IDH1 378/4885DYRK1A 4173/4885CSNK1D 1305/4885 |
| US-10287284-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | IDH1 378/4885DYRK1A 4173/4885CSNK1D 1305/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | IDH1 62/4885DYRK1A 3860/4885CSNK1D 1424/4885 |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | HBB, HBG1, HBG2 | IDH1 19/4885DYRK1A 4256/4885CSNK1D 1993/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | IDH1 72/4885DYRK1A 3837/4885CSNK1D 1536/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | IDH1 2914/4885DYRK1A 3015/4885CSNK1D 2078/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | IDH1 2914/4885DYRK1A 3015/4885CSNK1D 2078/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | IDH1 1325/4885DYRK1A 3704/4885CSNK1D 2154/4885 |
| US-10030011-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, PTGS2 | IDH1 378/4885DYRK1A 4173/4885CSNK1D 1305/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | IDH1 685/4885DYRK1A 2501/4885CSNK1D 353/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | IDH1 2241/4885DYRK1A 2930/4885CSNK1D 2060/4885 |
| US-10172840-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | IDH1 2914/4885DYRK1A 3015/4885CSNK1D 2078/4885 |
| US-10888569-B1 | Methods and compositions for treating cancer | BACH1, BCOR, BCCIP | IDH1 2365/4885DYRK1A 2798/4885CSNK1D 2706/4885 |
| US-20180291015-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | IDH1 378/4885DYRK1A 4173/4885CSNK1D 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.